Moreover, defects in apoptotic pathways and the deregulation of apoptotic proteins, such as Bcl-2, Bcl-xL and Mcl-1, play decisive roles in the development and therapy resistance of pancreatic cancer [28]. This evidence concerns the gene MCL1 and familial pancreatic carcinoma.